DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Quinapril (Quinapril Hydrochloride) - Indications and Dosage

 


Nutrilib.com
A comprihensive source of nutritional information

INDICATIONS AND USAGE

Hypertension

Quinapril hydrochloride tablets, USP are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using quinapril hydrochloride tablets, USP, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that quinapril hydrochloride tablets, USP do not have a similar risk (see WARNINGS).

Angioedema in Black Patients

Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.

DOSAGE AND ADMINISTRATION

Hypertension

Monotherapy

The recommended initial dosage of quinapril hydrochloride tablets, USP in patients not on diuretics is 10 or 20 mg once daily. Dosage should be adjusted according to blood pressure response measured at peak (2-6 hours after dosing) and trough (predosing). Generally, dosage adjustments should be made at intervals of at least 2 weeks. Most patients have required dosages of 20, 40, or 80 mg/day, given as a single dose or in two equally divided doses. In some patients treated once daily, the antihypertensive effect may diminish toward the end of the dosing interval. In such patients an increase in dosage or twice daily administration may be warranted. In general, doses of 40-80 mg and divided doses give a somewhat greater effect at the end of the dosing interval.

Concomitant Diuretics

If blood pressure is not adequately controlled with quinapril hydrochloride tablets, USP monotherapy, a diuretic may be added. In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally can occur following the initial dose of quinapril hydrochloride tablets, USP. To reduce the likelihood of hypotension, the diuretic should, if possible, be discontinued 2 to 3 days prior to beginning therapy with quinapril hydrochloride tablets, USP (see WARNINGS). Then, if blood pressure is not controlled with quinapril hydrochloride tablets, USP alone, diuretic therapy should be resumed.

If the diuretic cannot be discontinued, an initial dose of 5 mg quinapril hydrochloride tablets, USP should be used with careful medical supervision for several hours and until blood pressure has stabilized.

The dosage should subsequently be titrated (as described above) to the optimal response (see WARNINGS, PRECAUTIONS, and Drug Interactions).

Renal Impairment

Kinetic data indicate that the apparent elimination half-life of quinaprilat increases as creatinine clearance decreases. Recommended starting doses, based on clinical and pharmacokinetic data from patients with renal impairment, are as follows:

Patients should subsequently have their dosage titrated (as described above) to

Creatinine Clearance Maximum Recommended Initial Dose
>60 mL/min10 mg
30-60 mL/min5 mg
10-30 mL/min2.5 mg
<10 mL/minInsufficient data for Dosage recommendation

the optimal response.

Elderly (≥ 65 years)

The recommended initial dosage of quinapril in elderly patients is 10 mg given once daily followed by titration (as described above) to the optimal response. Following the initial dose of quinapril hydrochloride tablets, USP, the patient should be observed under medical supervision for at least two hours for the presence of hypotension or orthostatis and, if present, until blood pressure stabilizes. The appearance of hypotension, orthostasis, or azotemia early in dose titration should not preclude further careful dose titration. Consideration should be given to reducing the dose of concomitant diuretics.

DOSE ADJUSTMENTS IN PATIENTS WITH HEART FAILURE AND RENAL IMPAIRMENT OR HYPONATREMIA

Pharmacokinetic data indicate that quinapril elimination is dependent on level of renal function. In patients with heart failure and renal impairment, the recommended initial dose of quinapril is 5 mg in patients with a creatinine clearance above 30 mL/min and 2.5 mg in patients with a creatinine clearance of 10 to 30 mL/min. There is insufficient data for dosage recommendation in patients with a creatinine clearance less than 10 mL/min. (See WARNINGS, and PRECAUTIONS, Drug Interactions).

If the initial dose is well tolerated, quinapril may be administered the following day as a twice daily regimen. In the absence of excessive hypotension or significant deterioration of renal function, the dose may be increased at weekly intervals based on clinical and hemodynamic response.

HOW SUPPLIED

Quinapril hydrochloride tablets, USP are supplied as follows:

5-mg tablets: pink, film-coated, oval, standard convex tablets debossed with

, bisect and "5" on one side and "531" on the other side.

NDC 62037-531 -90 bottles of 90 tablets
NDC 62037-531 -10 bottles of 1000 tablets

10-mg tablets: pink, film-coated, round, standard convex tablets debossed with

and "10" on one side and "532" on the other side.

NDC 62037-532-90 bottles of 90 tablets
NDC 62037-532-10 bottles of 1000 tablets

20-mg tablets: pink, film-coated, round, standard convex tablets debossed with

and "20" on one side and "533" on the other side.

NDC 62037-533-90 bottles of 90 tablets
NDC 62037-533-10 bottles of 1000 tablets

40-mg tablets: pink, film-coated, round, standard convex tablets debossed with

and "40" on one side and "534" on the other side.

NDC 62037-534-90 bottles of 90 tablets
NDC 62037-534-10 bottles of 1000 tablets

Dispense in well-closed containers as defined in the USP.

STORAGE: Store at controlled room temperature 20 to 25°C (68 to 77°F) with excursions permitted between 15 to 30°C (59 to 86°F). (See USP.)

Protect from light.
Manufactured by:
Andrx Pharmaceuticals, Inc.
Ft. Lauderdale, FL 33314

Rev. date 03/06
7121

Page last updated: 2007-03-20

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008